Naltrexone Treatment of Alcohol Dependence
Launched by NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM (NIAAA) · Nov 2, 1999
Trial Information
Current as of March 18, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Meets criteria for current diagnosis of alcohol dependence.
- • Subjects used more than 15 standard alcohol drinks (average)/week with at least 1 day of 5 or more drinks in the past 30 days.
- • Successful completion of medical detoxification.
- • Lives within a commutable distance to the Treatment Research Center and agrees to follow-up visits.
- • Understands and signs the informed consent.
- Exclusion Criteria:
- • Current diagnosis of any substance dependence other than alcohol, nicotine, or marijuana.
- • Evidence of opiate use in the past 30 days.
- • Current treatment with psychotropic medications, including disulfiram (Antabuse) (excluding short-term use of benzodiazepines for detoxification).
- • History of unstable or serious medical illness, including need for opioid analgesics.
- • Severe physical or medical illnesses such as AIDS, active hepatitis, significant hepatocellular injury as evidenced by elevated bilirubin levels, and current severe psychiatric symptoms.
- • Use of an investigation medication in the past 30 days.
- • Female subjects who are pregnant, nursing, or not using reliable method of contraception.
About National Institute On Alcohol Abuse And Alcoholism (Niaaa)
The National Institute on Alcohol Abuse and Alcoholism (NIAAA) is a leading federal agency dedicated to advancing research on alcohol-related health issues and fostering a deeper understanding of alcohol use disorders. As part of the National Institutes of Health (NIH), NIAAA supports a diverse portfolio of clinical trials aimed at developing innovative prevention and treatment strategies for alcohol abuse and dependence. By collaborating with researchers, healthcare providers, and community organizations, NIAAA strives to translate scientific findings into effective public health initiatives, ultimately aiming to reduce the impact of alcohol on individuals and society.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Philadelphia, Pennsylvania, United States
People applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Discussion 0
Similar Trials